Grupo Espanol De Tumores Neuroendocrinos

6 trials 5 recruiting Academic / non-commercial

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

5 Recruiting

1 Completed trials

4 Countries active

11 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 1 Phase II: 4 Phase I/II: 1

Oversight events:

3 serious breaches across 2 trials

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Thyroid cancer 1

Top IMPs

CABOZANTINIB 1 ENFORTUMAB VEDOTIN 1 EVEROLIMUS 1 FLUOROURACIL 1 FOLINIC ACID 1 IRINOTECAN HYDROCHLORIDE TRIHYDRATE 1 L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE 1 LUTETIUM (177LU) EDOTREOTIDE 1 LUTETIUM (177LU) OXODOTREOTIDE 1 SACITUZUMAB GOVITECAN 1 TARLATAMAB 1

All trials

6 total

RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab Recruiting

2024-514327-42-00 Phase II 2 countries FLUOROURACIL; FOLINIC ACID; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; TARLATAMAB
Lu177-Dotatate every 16 weeks to reduce adverse events in patients with midgut neuroendocrine tumors Recruiting

2024-517921-14-00 Phase I/II 2 countries LUTETIUM (177LU) OXODOTREOTIDE
Multicenter, open label, single arm, phase II study to assess the efficay and safety of enfortumab-vedotin (EV) as a single agent in patient… Recruiting

2024-515511-21-00 Phase II 1 country ENFORTUMAB VEDOTIN
A multicenter, open label, two cohort, single arm, phase II study to evaluate the efficacy and safety of the anti-TROP2 antibody-drug conjug… Recruiting

2023-504898-20-00 Phase II 1 country SACITUZUMAB GOVITECAN
177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting

2022-502154-13-00 Phase III 4 countries EVEROLIMUS; L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) E…
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Ended

2024-511292-15-00 Phase II 1 country CABOZANTINIB

Showing 1–6 of 6 trials

← All sponsors A–Z